Welcome to our dedicated page for KALA BIO SEC filings (Ticker: KALA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on KALA BIO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into KALA BIO's regulatory disclosures and financial reporting.
Kala Bio insider Todd Bazemore, serving as Interim CEO, President and COO, reported a transaction on June 24, 2025 involving the sale of 4,058 shares of common stock at a weighted average price of $4.01 per share (range: $3.87-$4.12).
Key details of the transaction:
- Sale was executed under a 10b5-1 trading plan established on November 10, 2020
- Purpose: Cover tax withholding obligations related to RSU vesting from June 22, 2023 grant
- Post-transaction holdings: 83,699 shares (including 35,732 unvested RSUs) held directly
- Additional indirect ownership: 1 share held by son
The transaction was reported via Form 4 filing, signed by Mary Reumuth as attorney-in-fact on June 26, 2025, complying with SEC disclosure requirements for insider trading activity.
Kala Bio insider trading activity reported: Head of Research and Development and Chief Medical Officer Romulus K. Brazzell sold 5,251 shares of common stock on June 24, 2025, at a weighted average price of $4.01 per share (range: $3.87-$4.12).
Key details:
- Sale executed under a 10b5-1 trading plan established November 9, 2020
- Transaction purpose: Cover tax withholding obligations from RSU vesting granted June 22, 2023
- Post-transaction holdings: 82,698 shares, including 35,952 unvested RSUs
- Transaction form: Direct ownership
The sale was made in compliance with SEC regulations and followed a pre-established trading plan, indicating a routine transaction rather than a strategic investment decision.
Kala Bio (NASDAQ:KALA) filed a routine Form 4 reporting that director Mark T. Iwicki sold 13,227 common shares on June 24 2025 at a weighted-average price of $4.01 per share, generating roughly $53 000 in gross proceeds.
The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 9 2020 to cover tax-withholding obligations related to the vesting of restricted stock units (RSUs) granted on June 22 2023.
After the sale, Iwicki retains 258 433 shares, including 103 540 unvested RSUs, meaning the disposition represents slightly under 5 % of his prior beneficial ownership. No changes to company operations, strategy, or financial condition are disclosed.
Form 144 Notice of Proposed Sale filed for Kala Bio (NASDAQ: KALA) indicates an insider's intent to sell 5,251 shares of common stock with an aggregate market value of $21,056.51 through E*TRADE Financial Corporation. The planned sale is scheduled for June 24, 2025.
The securities being sold were originally acquired through a Restricted Stock Unit (RSU) vesting on June 24, 2025, where the insider received 16,450 shares as equity compensation. The total shares outstanding for Kala Bio are reported at 6,452,398.
Recent trading activity by the same seller through E*TRADE includes a previous sale of 3,687 shares on June 3, 2025, which generated gross proceeds of $13,789.38. This Form 144 filing represents the seller's declaration that they are not aware of any material adverse non-public information regarding the company.
KALA BIO, Inc. has filed a Form 144 indicating a proposed sale of 3,631 shares of its common stock. The shares are to be sold through E*TRADE Financial on or after 24 June 2025 on the NASDAQ exchange. At the reference market price, the transaction is valued at approximately $14,560. The company reports 6,452,398 shares outstanding, so the contemplated sale represents roughly 0.06% of the float.
The shares were acquired via the vesting of Restricted Stock Units (RSUs) issued as equity compensation on the same date. During the past three months, the same account sold 2,850 shares on 3 June 2025 for gross proceeds of $10,659.
Rule 144 filings are routine administrative notices required before certain affiliate or insider sales. Given the small size relative to total shares and the absence of any disclosed adverse information, the filing appears immaterial to the company’s fundamentals and is unlikely to influence trading dynamics.